Fount, fate, features, and function of renal erythropoietin-producing cells

Dahl, Sophie L.; Bapst, Andreas M.; Khodo, Stellor Nlandu; Scholz, Carsten C.; Wenger, Roland H.

doi:10.1007/s00424-022-02714-7

Cited by 14 publications

(4 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…419,420 LIE or KIE activation is crucial for HIF-2 to bind HRE promoter and induce EPO expression. 421,422 In liver, HIF-2, while the isolated HRE exhibits a preference for binding HIF-1α, the HRE within the native Epo 3' enhancer shows a stronger affinity for HIF-2α. 423 This preference is facilitated by cooperative interactions with other transcription factors that are bound to the promoter, the 3' enhancer, or other cis-acting sequences.…”

Section: Intracellular Interactions and Remote Regulations Of Hypoxia...mentioning

confidence: 99%

Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets

Zhao,

Xiong,

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects the survival of aerobic species and plays a prominent role in cardiovascular diseases. From the research history and milestone events related to hypoxia in cardiovascular development and diseases, The "hypoxia-inducible factors (HIFs) switch" can be observed from both temporal and spatial perspectives, encompassing the occurrence and progression of hypoxia (gradual decline in oxygen concentration), the acute and chronic manifestations of hypoxia, and the geographical characteristics of hypoxia (natural selection at high altitudes). Furthermore, hypoxia signaling pathways are associated with natural rhythms, such as diurnal and hibernation processes. In addition to innate factors and natural selection, it has been found that epigenetics, as a postnatal factor, profoundly influences the hypoxic response and progression within the cardiovascular system. Within this intricate process, interactions between different tissues and organs within the cardiovascular system and other systems in the context of hypoxia signaling pathways have been established. Thus, it is the time to summarize and to construct a multi-level regulatory framework of hypoxia signaling and mechanisms in cardiovascular diseases for developing more therapeutic targets and make reasonable advancements in clinical research, including FDA-approved drugs and ongoing clinical trials, to guide future clinical practice in the field of hypoxia signaling in cardiovascular diseases.

show abstract

Section: Intracellular Interactions and Remote Regulations Of Hypoxia...mentioning

confidence: 99%

Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets

Zhao,

Xiong,

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Сигналом к выработке эритропоэтина служит снижение парциального давления кислорода в крови. При нормальной оксигенации мРНК эритропоэтина в почечной ткани практически не определяется [10]. При развитии гипоксемии запускается транскрипция гена эритропоэтина (EPO).…”

Section: молекулярная биология эритропоэтинаunclassified

Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy

Семочкин

2022

Medicinskij sovet

View full text Add to dashboard Cite

Anemia is one of the most common symptoms of hematological malignancy and, on the other hand, a common complication of myelosuppressive anticancer therapy. Iron, vitamin B12, folate, biological analogs of human erythropoietin (EPO), and new targeted drugs (lenalidomide, luspatercept, roxadustat, etc.) are used in clinical practice to correct anemic syndrome in cancer patients. All these activators of erythropoiesis are combined into a single group called erythropoiesis-stimulating agents (ESAs). Issues of physiological regulation of erythropoiesis, historical information on the creation of recombinant human erythropoietin (rh-EPO), structural and biological characteristics of this group of drugs are covered in this literature review. In accordance with ESMO guidelines (2018), rh-EPO is indicated for patients receiving myelosuppressive chemotherapy with symptomatic anemia with Hb < 100 g/L and asymptomatic anemia with Hb < 80 g/L. ESAs are not used in patients not receiving chemotherapy, similarly to ASCO/ASH (2019) guidelines. Iron replacement therapy in patients receiving rh-EPO should be used regardless of whether there is an initial iron deficiency or not, since its functional deficiency occurs during treatment. The low-risk MDS is exception, where rh-EPO may be the mainstay of therapy. Low-risk MDS patients with endogenous EPO levels < 500 mIU/mL and a low transfusion load of less than 2 RBCs per month are optimal candidates for rh-EPO therapy. The article is illustrated by clinical observation of a patient with R-IPSS intermediate-risk MDS treated with epoetin alfa. The problems of prevention of thromboembolic complications associated with the use of ESA are also discussed.

show abstract

“…Tissue oxygenation regulates the production and release of EPO in response to hypoxia, as well as the expression of its receptor [4]. Epo dysregulation unavoidably leads to erythrocytes production disorder in the bone marrow [7].Abnormal endogenous erythropoietin production has been reported in lymphoproliferative disorder patients [8] . One results of this disorder causes anemia; Anemia is a common clinical characteristic that adversely affects the prognosis of B-CLL patients.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for iron metabolic disorders in newly diagnosed B-chronic lymphocytic leukemia patients

Saleem¹,

Awad²,

Alwan³

2022

ijhs

View full text Add to dashboard Cite

Due to the importance of increasing the incidence conditions of B cell chronic lymphocytic leukemia (B-CLL) that requiring accurate knowledge of the biology behind the pathogenesis and risks of this disease of each individual patient, this study was designed to investigate if hormonal alterations such as Hepcidin, Erythropoietin, and oxidant-antioxidant status may be useful in the understanding of B-CLL development in addition the relationship of these parameters with anemia in advance clinical stage in newly diagnosed patients with B-CLL. This study was conducted on 60 newly diagnosed patients with B-CLL and 30 control group .The socio-demographic information including (age and sex) and clinical data were collected for the period from 20 February until 25 December 2021. The result of the present study showed that out of the 60 newly diagnosed B-CLL patients, 39 was male and 21 was females, with the mean age ( 64.04 ± 5.6 ) years and out of the 30 controls group ,12 was males and 18 was females with the mean age of ( 63.33 ± 4.70) years .therefore, it was a higher prevalence p value ≤0.05 of newly diagnosed B-CLL patients in males (65.0 %) compare to females (35.0 % ).

show abstract

Fount, fate, features, and function of renal erythropoietin-producing cells

Cited by 14 publications

References 129 publications

Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets

Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets

Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy

Risk factors for iron metabolic disorders in newly diagnosed B-chronic lymphocytic leukemia patients

Contact Info

Product

Resources

About